Groove Botanicals 3Q 2026: Revenue $0, EPS ($0.00) — 10-Q Summary

Groove Botanicals reported zero revenue and a narrowed net loss of $86,180 for 3Q 2026. Operating expenses increased, but lower SG&A expenses and other income offset higher legal costs. Diluted EPS was ($0.00).

Original reporting
Published Nov 12, 2026, 3:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 3:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Groove Botanicals 3Q 2026: Revenue $0, EPS ($0.00) — 10-Q Summary — source image
Decision brief

The 30-second read

$GRVEBearishLow
01

Why it matters

The filing confirms ongoing financial challenges, likely keeping the stock under pressure.

02

Market read

Primary disclosure of quarterly results for a microcap; limited trading relevance due to small scale.

03

What to watch

Legal expenses may be one-time; future revenue could improve with product launches.

Relevance 6/10Novelty 6/10Timing: post filing release

Background

Groove Botanicals filed its Q3 2026 10-Q, reporting zero revenue and a modest net loss.

Company-level read

Ticker impact

$GRVEBearishMedium confidence
Context

Quarterly 10-Q shows revenue of $0 and a narrowed net loss of $86.18K, with higher legal expenses and lower SG&A.

Expected impact

likely downside as market prices in the continued loss and higher legal costs

Evidence & confidence

Microcap with minimal revenue and a net loss signals limited upside; investors may sell on the negative earnings surprise.

Market effects

Limited impact on broader sector; highlights challenges for early-stage botanical product companies.

No significant regional effect.

Minimal global relevance.

Counterpoint

Potential upside if the company secures future contracts or funding despite current losses.

Key entities

  • Groove Botanicals Inc.

    Microcap biotech firm reporting Q3 2026 results.

Related articles

$FLNTMed

What Fluent (FLNT) Said on Its Q3 Earnings Call

Fluent (FLNT) reported a Q3 net loss of $3.1M, improved from last year. Adjusted EBITDA loss narrowed to $43K, with positive EBITDA expected in Q4. Cash decreased to $11.4M, with $31.5M in short-term debt. The company guided toward high 20% gross margins and potential double-digit revenue growth in 2027, while testing in-store and loyalty offerings.

$AMATMed

What Applied Materials (AMAT) Said on Its Q4 Earnings Call

Applied Materials (AMAT) expects Semiconductor Systems revenue to grow over 40% in 2026, with advanced packaging and inspection/metrology revenue rising 90% and 50% respectively. The company faces capacity constraints but plans to double output by 2028. Management sees strong demand in DRAM and logic, with services growth at 15%. China's share of business is expected to fall below 25% in 2027. AMAT reaffirmed long-term targets for market share, margins, and service revenue growth.

$AGROHighAI 8/10

Adecoagro (AGRO) Q3 2026 Earnings Call Transcript

Adecoagro reported Q3 2026 earnings, with gross sales of $591M and year-to-date sales of $1.5B. Fertilizers drove growth, offsetting lower Sugar, Ethanol, and Energy revenues. Adjusted EBITDA reached a 9-month high. The company acquired the Caarapó mill, expecting it to boost crushing volumes. Fertilizers and Food/Agriculture segments performed strongly, while Sugar/Ethanol faced cost pressures and lower sales.

$FIGRHighAI 8/10

Figure Tech (FIGR) Q3 2026 Earnings Call Transcript

Figure Tech (FIGR) reported Q3 2026 earnings with $5.8B volume, up 107% YoY, and 58% EBITDA margin. The company processed $5.1B organically and $0.7B from Kiavi. Figure Connect accounted for 72% of volume. They added 612 partners, expanded SMB business to $500M run rate, and launched new AI-driven products. Kiavi acquisition added $8B volume and new asset classes, expected to be accretive. The company saw resilience in higher interest rates, with strong investor demand and securitizations.

$CDNLMedAI 8/10

Cardinal Infra (CDNL) Q3 2026 Earnings Call Transcript

Cardinal Infra (CDNL) reported Q3 2026 revenue of $202M, up 65%, but adjusted EBITDA fell to $9M from $21M YoY. The company withdrew full-year guidance due to project estimate revisions and operational challenges. The board authorized a $50M share repurchase program. CFO Mike Rowe will step down, and the company is focusing on improving execution and profitability.